VSee Health, Inc. announced a 20-fold expansion of its hospital network to 58 locations over approximately two years, driving an 80% revenue increase to $11.4 million in 2025. The telehealth and digital health solutions provider attributes this growth to expanding Integrated Delivery Network relationships and multi-year deployments. Following the strategic sale of VSee Lab on May 31, 2026, the company reduced annual operating expenses by approximately $6.0 million and sharpened its focus on the iDoc telehealth platform.

Financial Performance

The company's financial data reflects the impact of its streamlined operations and renewed focus on core digital health offerings.

Future Outlook

VSee Health Chairman and Chief Executive Officer Dr. Imoigele Aisiku stated that the company has become a pure-play enterprise telehealth provider and reached a major inflection point. He noted that the team expects to expand its reach to hundreds of hospitals over the next two years. With the hospital network growing and margins improving, the company believes achieving a $20 million annual revenue run-rate, sustained gross margins of at least 50%, and progress toward profitability are realistic targets.

VSee Health has completed the strategic separation of its laboratory subsidiary, VSee Lab, and retired approximately 7% of its outstanding common stock to streamline operations and sharpen its focus on telehealth. Under a Stock Purchase Agreement dated May 31, 2026, VSee Health sold 100% of VSee Lab, Inc. to former Co-Chief Executive Officer and Chairman Milton Chen. As part of the transaction, Chen transferred all 2,870,069 shares of VSee Health common stock owned by him back to the company and assumed responsibility for the remaining liabilities of VSee Lab following closing.

The returned shares represent approximately 7% of the company's outstanding common stock. This move is expected to significantly improve shareholder alignment and simplify the company's capital structure. Concurrent with the closing, Milton Chen resigned as Co-Chief Executive Officer and Chairman of the Board. Dr. Imoigele Aisiku has assumed the roles of sole Chief Executive Officer and Chairman of the Board.

Strategic Benefits and Leadership Transition

The transaction marks a significant milestone in VSee Health's ongoing effort to improve financial performance and position the company for long-term growth. The company outlined several key benefits resulting from the separation:

• Complete separation of the VSee Lab business from VSee Health.
• Elimination of a non-core and operationally distracting division.
• Retirement of approximately 7% of outstanding common shares.
• Streamlined leadership under a single Chief Executive Officer.
• Enhanced focus on the Company's iDoc telehealth platform and enterprise healthcare solutions.

"This transaction represents a decisive turning point for VSee Health," said Dr. Aisiku. "We now have a simpler corporate structure, a stronger alignment with shareholders, and a singular focus on scaling iDoc and our enterprise telehealth platform. Every dollar, every resource, and every member of our team is focused on growth, execution, and building long-term shareholder value."

Future Outlook

With the transaction completed, VSee Health has eliminated a significant source of operational complexity. The company plans to devote its full attention to expanding its telehealth platform, healthcare enterprise relationships, AI-enabled care solutions, and recurring revenue opportunities. Management believes the company is emerging from this transaction with a clearer strategic direction, a stronger balance sheet, improved governance, and a more focused operating model.

The company expects the benefits of the divestiture to be reflected in future operating performance. VSee Health believes it is now better positioned to pursue growth initiatives, strategic partnerships, acquisitions, and shareholder value creation.